# A Study of Canagliflozin and Metformin Immediate Release (150 mg/500 mg) FDC Tablets in Healthy Volunteers

> **NCT01508182** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 64 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Canagliflozin tablets
- **DRUG:** Metformin IR tablets
- **DRUG:** Canagliflozin/metformin IR FDC tablets
- **DRUG:** Canagliflozin tablets
- **DRUG:** Metformin IR tablets
- **DRUG:** Canagliflozin/metformin IR FDC tablets

## Key facts

- **NCT ID:** NCT01508182
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2012-03
- **Final completion:** 2012-03
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2013-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01508182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01508182, "A Study of Canagliflozin and Metformin Immediate Release (150 mg/500 mg) FDC Tablets in Healthy Volunteers". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT01508182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*